SCHEMBL17680436

SCHEMBL17680436

Cc1cc(-c2cnn(C)c2)c([N+](=O)[O-])cc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.46
LRRK2 Q5S007 1/20 0.41
MAPT P10636 1/20 0.41
AURKA O14965 1/20 0.41
TTK P33981 1/20 0.41
AURKB Q96GD4 1/20 0.41
INCENP Q9NQS7 1/20 0.41
SMARCA2 P51531 1/20 0.40
SMARCA4 P51532 1/20 0.40
MAP4K4 O95819 1/20 0.38
CYP3A4 P08684 3/20 0.36
ALDH1A1 P00352 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
BRD4 O60885 1/20 0.36
TSHR P16473 3/20 0.36
RECQL P46063 1/20 0.36
PIK3CA P42336 2/20 0.35
PIK3CG P48736 3/20 0.35
PIK3CD O00329 2/20 0.35
PIK3CB P42338 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17683760 0.83 ERN1 (0.44) ERN1LRRK2AURKATTKAURKB
SCHEMBL17680437 0.79 ERN1 (0.47) ERN1LRRK2MAPTBRD4CREBBP
SCHEMBL866951 0.77 CYP3A4 (0.52) MAPTCYP3A4ALDH1A1TDP1TSHR
SCHEMBL30932744 0.77 CYP3A4 (0.52) MAPTCYP3A4ALDH1A1TDP1TSHR
SCHEMBL19175137 0.75 ERN1 (0.44) ERN1LRRK2MAPTCYP3A4ALDH1A1
SCHEMBL376601 0.75 MAPT (0.63) ERN1MAPTAURKATTKAURKB
SCHEMBL28917966 0.74 CYP3A4 (0.53) MAPTCYP3A4ALDH1A1TDP1TSHR
SCHEMBL22652108 0.73 ERN1 (0.52) ERN1MAPTTTKBRD4TSHR
SCHEMBL16134054 0.73 MAPT (0.58) ERN1MAPTCYP3A4ALDH1A1TDP1
SCHEMBL6374348 0.73 ALDH1A1 (0.54) ERN1SMARCA2SMARCA4ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9593098-B2 Compounds and compositions for modulating EGFR mutant kinase activities YUHAN CORPORATION (KR) 2017-03-14 US disclosed
US-20160102076-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES YUHAN CORPORATION 2016-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102076-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES EGFR, ERBB2, ERBB3 ERN1 582/4885LRRK2 823/4885MAPT 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.